Chemoinformaics analysis of 1,3,5,5-Tetramethyl-1,3-cyclohexadiene
| Molecular Weight | 136.238 | nRot | 0 |
| Heavy Atom Molecular Weight | 120.11 | nRig | 6 |
| Exact Molecular Weight | 136.125 | nRing | 1 |
| Solubility: LogS | -3.393 | nHRing | 0 |
| Solubility: LogP | 3.333 | No. of Aliphatic Rings | 1 |
| Acid Count | 0 | No. of Aromatic Rings | 0 |
| Base Count | 0 | No. of Aliphatic Carbocycles Rings | 1 |
| Atoms Count | 26 | No. of Aliphatic Hetero Cycles | 0 |
| No. of Heavy Atom | 10 | No. of Aromatic Carbocycles | 0 |
| nHetero | 0 | No. of Aromatic Hetero Cycles | 0 |
| nBridge Head | 0 | No. Saturated Carbocycles | 0 |
| No. of Hydrogen atom | 16 | No. of Saturated Hetero Cycles | 0 |
| No. of Carbon atom | 10 | No. of Saturated Rings | 0 |
| No. of Nitrogen atom | 0 | No. of Arom Atom | 0 |
| No. of Oxygen atom | 0 | No. of Arom Bond | 0 |
| nHA | 0 | APOL | 27.3687 |
| nHD | 0 | BPOL | 16.0513 |
| QED | 0.479 |
| Synth | 3.227 |
| Natural Product Likeliness | 1.541 |
| NR-PPAR-gamma | 0.005 |
| Lipinski | Accepted |
| Pfizer | Rejected |
| GSK | Accepted |
| Golden Triangle | Rejected |
| Pgp-inh | 0.08 |
| Pgp-sub | 0.001 |
| HIA | 0.009 |
| CACO-2 | -4.504 |
| MDCK | 0.0000184 |
| BBB | 0.56 |
| PPB | 0.806562 |
| VDSS | 2.372 |
| FU | 0.375077 |
| CYP1A2-inh | 0.609 |
| CYP1A2-sub | 0.915 |
| CYP2c19-inh | 0.737 |
| CYP2c19-sub | 0.924 |
| CYP2c9-inh | 0.317 |
| CYP2c9-sub | 0.833 |
| CYP2d6-inh | 0.566 |
| CYP2d6-sub | 0.908 |
| CYP3a4-inh | 0.034 |
| CYP3a4-sub | 0.381 |
| CL | 4.23 |
| T12 | 0.778 |
| hERG | 0.019 |
| Ames | 0.003 |
| ROA | 0.02 |
| SkinSen | 0.932 |
| Carcinogencity | 0.269 |
| EI | 0.978 |
| Respiratory | 0.222 |
| NR-Aromatase | 0.013 |
| Antiviral | No |
| Prediction | 0.941956 |